August 14, 2025 — Leads & Copy — OS Therapies Inc. (NYSE American: OSTX) will report its second quarter 2025 financial results, for the period ended June 30, 2025, and provide a business update on Tuesday, August 19, 2025.
OS Therapies is focused on treatments for Osteosarcoma (OS) and other solid tumors. The company’s lead asset, OST-HER2, is an immunotherapy that leverages the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency.
The Company anticipates submitting a Biologics Licensing Application (BLA) to the U.S. FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher. The company is also advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates.
OS Therapies Contact Information:
Investor Relations
Harrison Seidner, PhD
WaterSeid Partners
OSTX@waterseid.com
Public Relations
Stephanie Chen
Elev8 New Media
stephanie@elev8newmedia.com
Source: OS Therapies Inc.
